| 名稱 | Mocetinostat |
| 描述 | Mocetinostat (MG0103) is an orally available HDAC inhibitor with most potency for HDAC1 (IC50: 0.15 μM), 2- to 10- fold selectivity against HDAC2/3/11. |
| 細(xì)胞實(shí)驗(yàn) | Cells were transfected with antisense oligonucleotides for 4 h everyday for 2 d. At 48 h after initial transfection, cells were harvested and apoptosis was evaluated with the Cell Death Detection ELISA Plus kit following the manufacturer's protocol. In all experiments, a fixed amount of DNA-histone complex, provided with the ELISA kit as a positive control, was used to ensure results were comparable among experiments. To analyze caspase-dependent apoptosis, an antibody specifically recognizing the caspase cleavage fragment of human poly(ADP-ribose) polymerase (PARP) was used to probe Western blots of lysates from cells treated with MGCD0103 [1]. |
| 激酶實(shí)驗(yàn) | The deacetylase enzyme assay was based on a homogeneous fluorescence release assay. Purified recombinant HDAC enzymes were incubated with compounds diluted in various concentrations for 10 min in assay buffer [25 mmol/L HEPES (pH 8.0), 137 mmol/L NaCl, 1 mmol/L MgCl2, 2.7 mmol/L KCl] at room temperature. The substrate Boc-Lys(ε-Ac)-AMC was added to the reaction for further incubation at 37°C. The concentration of the substrate and the incubation time varied for different isotypes of HDAC enzymes. A 20-min trypsin incubation at room temperature allowed the release of the fluorophore from the deacetylated substrate. The fluorescent signal was detected by fluorometer at excitation of 360 nm, emission of 470 nm, and cutoff at 435 nm. The IC50 values of the compounds were determined by analyzing dose-response inhibition curves [1]. |
| 動(dòng)物實(shí)驗(yàn) | Female CD-1 nude mice, ages 8 to 10 wk, were used. Tumor fragments (～30 mg), which had been serially passaged thrice in vivo in minimal, were implanted s.c. through a small surgical incision on the flank of the mice while under general anesthesia. HDAC inhibitors were dissolved in vehicle (PBS acidified with 0.1 N HCl or PEG400/0.2 N HCl saline, 40:60) and dosed p.o. as solutions daily. Tumor volumes and body weight were monitored thrice weekly for at least 2 wk. Each experimental group contained six to eight animals. For pharmacokinetic study, blood was collected from animals at various time points, and plasma samples were analyzed using an HPLC system coupled with a triple quadrupole mass spectrometer [1]. . Forty rats (220 ± 20?g) were randomly divided into four different dosages of MGCD0103 groups (Low group, Medium group, High group, and control group with 10 rats in each group). MGCD0103 was dissolved in corn oil as suspension at three different concentrations (20, 40, and 80?mg/mL). Three different MGCD0103 groups (Low group, Medium group, and High group) were respectively given MGCD0103 20, 40, and 80?mg/kg one time by intragastric administration at every morning and last for 7 days. Control group were given saline by same administration method. At 8 days morning, six probe drugs, bupropion, phenacetin, tolbutamide, metoprolol, testosterone, and omeprazole, were mixed in corn oil and given to the rats of three MGCD0103 groups and control group by intragastric administration at a single dosage of 10?mg/kg for bupropion, phenacetin, metoprolol, testosterone, and omeprazole and 1?mg/kg for tolbutamide. Blood (0.3?mL) samples were collected into heparinized 1.5?mL polythene tubes from the tail vein at 0.0833, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, and 48?h after intragastric administration of six probe drugs. 100?μL of plasma was obtained from blood sample after centrifugation at 4000?g for 10?min. In a 1.5?mL centrifuge tube, 200?μL of acetonitrile (containing 50?ng/mL IS) was added into 100?μL of collected plasma sample. After vortex-mixing for 1.0?min, the sample was centrifuged at 13000?g for 15?min. Then supernatant (2?μL) was injected into the UPLC-MS/MS system for analysis. Concentration of plasma probe drugs versus time was analyzed by Version 3.0 Data Analysis System. The main pharmacokinetic parameters of the MGCD0103 group and control group were analyzed by SPSS l8.0 statistical software [3]. |
| 體外活性 | Mocetinostat (MGCD0103) 在體外有效針對人類HDAC1并對HDAC2、HDAC3和HDAC11也有抑制作用。在完整細(xì)胞中，MGCD0103僅抑制了總HDAC活性的一部分，并且即使在藥物移除后也顯示出持久的抑制活性。MGCD0103誘導(dǎo)組蛋白過度乙酰化，選擇性誘導(dǎo)凋亡，并且在多種人類癌癥細(xì)胞系中以劑量依賴的方式導(dǎo)致細(xì)胞周期阻滯[1]。MGCD0103在體外的多種人類癌癥細(xì)胞系中以及體外的人類外周白細(xì)胞(WBC)中劑量依賴性地抑制HDAC活性。MGCD0103的HDAC抑制活性是時(shí)間依賴的，在外周WBC中至少持續(xù)24小時(shí)[2]。 |
| 體內(nèi)活性 | 在體內(nèi)，Mocetinostat顯著以劑量依賴的方式抑制裸鼠體內(nèi)人類腫瘤異種移植物的生長，其抗腫瘤活性與腫瘤中組蛋白乙?；恼T導(dǎo)相關(guān)[1]。Mocetinostat的抑制活性在裸鼠體內(nèi)至少持續(xù)8小時(shí)，在固體腫瘤患者中持續(xù)48小時(shí)。在癌癥患者中，Mocetinostat持續(xù)的藥效僅通過外周WBC中劑量依賴的酶抑制得以觀察到，而非通過組蛋白乙?；治鯷2]。以高劑量通過胃內(nèi)給藥7天的MGCD0103，輕微誘導(dǎo)大鼠的托布他胺代謝。Mocetinostat未能誘導(dǎo)或抑制CYP1A2、CYP2B1、CYP2D4和CYP3A2酶的活性[3]。MGCD0103改善了肺動(dòng)脈加速時(shí)間，并減少了肺動(dòng)脈流動(dòng)輪廓的收縮期凹陷[4]。 |
| 存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 11 mg/mL (27.7 mM)
H2O : < 1 mg/mL (insoluble or slightly soluble)
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
|
| 關(guān)鍵字 | HDAC | Histone deacetylases | Mocetinostat | Autophagy | Apoptosis | inhibit | MGCD 0103 | MGCD-0103 | MG-0103 | MG 0103 | Inhibitor |
| 相關(guān)產(chǎn)品 | Guanidine hydrochloride | Naringin | Taurine | Gefitinib | Hydroxychloroquine | 5-Fluorouracil | Curcumin | Stavudine | Tributyrin | L-Ascorbic acid | Paeonol | Sodium 4-phenylbutyrate |
| 相關(guān)庫 | 抑制劑庫 | 經(jīng)典已知活性庫 | 抗癌活性化合物庫 | 抗癌上市藥物庫 | 已知活性化合物庫 | 抗衰老化合物庫 | 藥物功能重定位化合物庫 | NF-κB 通路分子庫 | 抗癌臨床化合物庫 | 抗癌藥物庫 |